Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Cornelius A. Thiels

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3654-8601; OpenAlex author ID A5047120387. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 2, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 5 papers, 1 trial · 2025: 5 papers · 2026: 9 papers

Papers 24

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Co-author DOI 10.1002/jso.70292↗
  2. Disparities in Pancreatic Cancer Survival: The Overlooked Role of Demographic and Socioeconomic Factors. Co-author DOI 10.1002/jso.70377↗
  3. Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database. Co-author DOI 10.1007/s12029-026-01545-4↗
  4. A decade of pancreatoduodenectomy outcomes for pancreatic adenocarcinoma: 2014-2023 analysis of the N SQIP pancreatectomy PUF database: A decade of pancreatodu… Last author DOI 10.1016/j.hpb.2026.01.016↗
  5. Nationwide Trends in Neoadjuvant Chemotherapy Utilization for Pancreatic Adenocarcinoma From 2012 to 2021. Co-author DOI 10.1016/j.jss.2026.09.037↗
  6. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  7. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  8. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
  9. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? First author DOI 10.6004/jnccn.2025.7097↗
  10. Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/jso.27871↗
  11. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  12. Long-Term Reoperation Rates Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Last author DOI 10.1177/00031348241304021↗
  13. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  14. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  15. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients. Last author DOI 10.1002/jso.27837↗
  16. The Emerging Role of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pancreatic Cancer. Co-author DOI 10.1002/jso.27880↗
  17. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection. Last author DOI 10.1016/j.hpb.2023.09.010↗
  18. Quality of Life and Gastrointestinal Symptoms in Long-term Survivors of Pancreatic Cancer Following Pancreatoduodenectomy. Last author DOI 10.1097/sla.0000000000006053↗
  19. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  20. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  21. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  22. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-023-14138-3↗
  23. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  24. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. First author DOI 10.1002/cam4.4144↗

Trials 1

  1. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis Principal investigator NCT04858009↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 17 shared papers, 2021–2026 · strength 3.34
  2. Susanne Gray Warner · 14 shared papers, 2022–2026 · strength 2.98
  3. Michael L. Kendrick · 14 shared papers, 2021–2026 · strength 2.68
  4. Travis Edward Grotz · 10 shared papers, 2021–2026 · strength 2.08
  5. Sean Patrick Cleary · 11 shared papers, 2021–2026 · strength 2.04
  6. Zhi Ven Fong · 4 shared papers, 2026 · strength 1.17
  7. John Andrew Stauffer · 4 shared papers, 2026 · strength 1.17
  8. Katherine E. Poruk · 4 shared papers, 2026 · strength 1.17
  9. Robert R. McWilliams · 5 shared papers, 2022–2026 · strength 0.93
  10. Chi Zhang · 4 shared papers, 2024–2025 · strength 0.89
  11. Jennifer A. Yonkus · 5 shared papers, 2022–2025 · strength 0.85
  12. Andrea Zironda · 4 shared papers, 2024–2025 · strength 0.84
  13. Jennifer L. Leiting · 4 shared papers, 2022–2026 · strength 0.68
  14. Amro M. Abdelrahman · 3 shared papers, 2022–2025 · strength 0.51
  15. Roberto Alva‐Ruiz · 3 shared papers, 2022–2025 · strength 0.48
  16. Ryan Michael Carr · 2 shared papers, 2025–2026 · strength 0.43
  17. Freek D. Daams · 2 shared papers, 2026 · strength 0.37
  18. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.37
  19. Oskar Franklin · 2 shared papers, 2026 · strength 0.37
  20. Patrik Larsson · 2 shared papers, 2026 · strength 0.37
  21. Ernesto Sparrelid · 2 shared papers, 2026 · strength 0.37
  22. Bas Groot Koerkamp · 2 shared papers, 2026 · strength 0.37
  23. Poya Ghorbani · 2 shared papers, 2026 · strength 0.37
  24. Thomas F. Stoop · 2 shared papers, 2026 · strength 0.37
  25. Hiroyuki Ishida · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.